Side-by-side · Research reference

CrystagenvsDermorphin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED12/40 cited

BAnimal-StrongHUMAN-REVIEWED20/47 cited

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

Dermorphin

Opioid Peptide · μ-Receptor Agonist · Research Only

~30×Morphine potency

μ-selectiveReceptor typeNegri 1992

D-Ala²Unique featureAmiche 1998

Research only · ICV / SC (animal models)

01Mechanism of Action

Parameter

Crystagen

Dermorphin

Primary target

B-lymphocytes in splenic tissueСhervyakova 2014

μ-opioid receptors (central and peripheral)Negri 1992 Steel 2014

Pathway

B-cell activation → Immune modulation during agingСhervyakova 2014

μ-receptor activation → G-protein coupling → adenylyl cyclase inhibition → neuronal hyperpolarization

Downstream effect

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Potent analgesia, reduced nociceptive signaling, opioid-mediated CNS and peripheral effects

Feedback intact?

Unknown — bioregulator mechanism not fully characterized

N/A — exogenous opioid agonist

Origin

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Phyllomedusa sauvagei and P. bicolor frog skin — gene-encoded with natural D-amino acid incorporationAmiche 1998 Mignogna 1992

Antibody development

—

Site-directed antibodies produced for detection and purificationCucumel 1996

02Dosage Protocols

Parameter

Crystagen

Dermorphin

Standard dose

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

—

Evidence basis

Animal / mechanistic

Animal studies · In vitro assays

Route

Subcutaneous (presumed from bioregulator class)

—

Frequency

Unknown — bioregulator protocols variable

—

Duration

Unknown — chronic administration presumed in animal models

—

Half-life

Not reported

—

Legal status

—

Controlled substance in many jurisdictions · Research only

Not approved for human use.

Animal research (ICV)

—

Low nanomolar to picomolar range

Intracerebroventricular administration in rodent models.

Detection limit (doping)

—

5 pg/mL in equine plasma/urineSteel 2014

High-throughput LC-MS/MS screen developed for racing industry.

Duration of action

—

10–120 minutes (dose-dependent, intrathecal)

Human toxicity

—

Kambô ritual (P. bicolor skin) — violent emesis, vasodilation, fluid shifts, ADH dysregulationTran 2025

04Side Effects & Safety

Parameter

Crystagen

Dermorphin

Published adverse events

None reported in available animal literature

—

Human safety data

Absent — no controlled human trials identified

—

Autoimmune considerations

Theoretical concern with B-cell modulators in predisposed individuals

—

Opioid effects

—

Respiratory depression, sedation, euphoria, tolerance, dependence risk

CNS effects

—

Analgesia (high-affinity sites), catalepsy (low-affinity sites)Negri 1992

Kambô ritual toxicity

—

Violent emesis, vasodilation, profound fluid shifts, hyponatremia, ADH dysregulation, brain death (case report)Tran 2025

Peripheral effects

—

GI motility inhibition (ileum > vas deferens in vitro)Negri 1992

Receptor selectivity caveat

—

Two μ-receptor subtypes — differential behavioral effects (analgesia vs. catalepsy)Negri 1992

Proteolytic stability

—

Tyr³-Pro⁶ bond relatively unstable; endogenous enzymes may produce tetrapeptide fragmentsCucumel 1996

Absolute Contraindications

Crystagen

·Active autoimmune disease (theoretical)

Dermorphin

·Human use — not approved by any regulatory authority
·Controlled substance status — possession illegal in many jurisdictions
·Known opioid hypersensitivity or respiratory compromise

Relative Contraindications

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

Dermorphin

·Any context outside approved animal research protocols
·CNS depressant co-administration

05Administration Protocol

Parameter

Crystagen

Dermorphin

1. Route

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

Dermorphin is a controlled substance in many jurisdictions and is not approved for human use. Possession, synthesis, or distribution may be illegal. Use is restricted to licensed research settings under institutional review.

2. Reconstitution

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

In rodent models, intracerebroventricular (ICV) or intrathecal injection is used at nanomolar to picomolar concentrations. Subcutaneous administration also documented. All protocols require IACUC approval.

3. Timing

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

High-throughput LC-MS/MS screens developed for anti-doping programs detect dermorphin and 17 related peptides in equine and human urine/plasma at limits as low as 5 pg/mL.Steel 2014

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

Application of Phyllomedusa bicolor skin secretions to superficial burns. Not recommended — associated with severe toxicity including violent emesis, hyponatremia, and documented case of brain death.Tran 2025

06Stack Synergy

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014

Dermorphin

— no documented stacks